HCC Liver-Link program to reduce racial gaps in liver cancer care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multi-center, randomized pilot comparing the HCC Liver-Link intervention to usual care in 40 Black patients with BCLC stage 0, A, or downstaged B HCC. The intervention combines culturally tailored patient education, social needs and substance use screening with referrals, and facilitated access to subspecialty care through a multidisciplinary HCC tumor board. Participants are randomized and followed for six months or until liver transplant waitlisting. Primary outcomes are time to receipt of curative therapies and change in HCC-related knowledge to inform larger future interventions.

Why it matters

Who can join: the full rules

Inclusion Criteria

• Within UCSF criteria:

Candidates are eligible or a standardized MELD or PELD exception if, before completing locoregional therapy, they have lesions that meet one of the following criteria:

* One Class 5 lesion greater than 5 cm and less than or equal to 8 cm
* two or three Class 5 lesions that meeting all of the following

  * At least one lesion greater than 3cm
  * Each lesion less than or equal to 5 cm, and
  * A total diameter of all lesions less than or equal to 8cm
* Four or five Class 5 lesions each less than 3 cm, and a total diameter of all lesions less than or equal to 8 cm.
* Between 18-75 years old
* Have no more than two visits with an HCC-related provider
* Able to read, write, and speak English
* Any 1 of the following:

  * Self-report as Black race (can be multiple races as long as 1 is Black)
  * Self-report as insured by Medicaid (+/- Medicare)
  * SVI (Social vulnerability index) \>= .75
  * Unmarried

Exclusion Criteria

* Lacks capacity to provide informed consent, including those with stage 2 HE or higher at the time of consent.
* Age over 75
* Last transthoracic echocardiogram with EF\<40% (OK if no prior echo)
* BMI over 50
* Patients who, in the investigator's judgment, are unlikely to ever be eligible for liver transplantation or resection at the time of enrollment, with reason documented
* Prior history of any solid organ transplant
* Non-skin cancer malignancies other than hepatocellular carcinoma in past 2 years unless approved by PI (i.e. cervical cancer, early prostate cancer)
* Patients who have undergone resection or waitlisted
* Patients near completion of transplant evaluation, PI to determine utility of intervention.

Where it's running

• Indiana University School of Medicine
  Indianapolis, Indiana, United States Recruiting
• Johns Hopkins University
  Baltimore, Maryland, United States Recruiting

Study contacts

• Study coordinator: Savannah Yarnelle
• Email: samussel@iu.edu
• Phone: (317) 278-6424

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized Neoantigen Vaccine Plus IL-12 in High-Risk Hepatocellular Carcinoma

  This study tests a personalized DNA vaccine plus IL-12 to see if it helps people who have high-risk liver cancer after tumor removal.

  Recruiting at 4 sites Phase 2 Geneos Therapeutics · Atlanta, Georgia and 8 other locations · NCT07722741

• VRT106 plus camrelizumab and apatinib for advanced HCC in patients who have tried prior ICIs

  This study tests VRT106, with camrelizumab and apatinib, to see if it helps people with advanced hepatocellular carcinoma who have already had prior immune checkpoint inhibitors fail.

  Recruiting Phase 2/3 Guangzhou Virotech Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07589244

• Y-90 microspheres with camrelizumab and/or apatinib versus Y-90 alone or cTACE for unresectable liver cancer

  This trial will test whether adding camrelizumab and/or apatinib to Y-90 microsphere treatment helps people with unresectable, non-metastatic hepatocellular carcinoma more than Y-90 alone or conventional TACE.

  Recruiting at 2 sites Phase 2 GrandPharma (China) Co., Ltd. · Beijing and 2 other locations · NCT07334483

• How genes and alcohol interact to affect liver cancer risk

  This project will test if certain gene variants together with alcohol use and metabolic problems raise the risk of liver cancer in people with fatty or cryptogenic liver disease, especially men with diabetes or obesity.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan, Milano · NCT07272200

• MRI-guided adaptive single-session radiation for liver tumors (SABR)

  This trial will test a single-session, MRI-guided adaptive high-dose radiation (SABR) for adults with primary or metastatic liver tumors to see if on-table MRI planning and replanning can treat tumors without a separate simulation visit.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT07223307

• Using contrast-enhanced ultrasound to check Y-90 radioembolization response in liver cancer

  This will test whether contrast-enhanced ultrasound (CEUS) can show treatment response to Y‑90 radioembolization in people with newly diagnosed hepatocellular carcinoma who are scheduled for TARE.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07145801

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.